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Abstract
Background: Vascular occlusion during liver resection results in ischaemia-reperfusion (IR) injury, which
can lead to liver dysfunction. We performed a systematic review and meta-analysis to assess the benefits
and harms of using various pharmacological agents to decrease IR injury during liver resection with
vascular occlusion.
Methods: Randomized clinical trials (RCTs) evaluating pharmacological agents in liver resections con-
ducted under vascular occlusion were identified. Two independent reviewers extracted data on popula-
tion characteristics and risk of bias in the trials, and on outcomes such as postoperative morbidity,
hospital stay and liver function.
Results: A total of 18 RCTs evaluating 17 different pharmacological interventions were identified. There
was no significant difference in perioperative mortality, liver failure or postoperative morbidity between the
intervention and control groups in any of the comparisons. A significant improvement in liver function was
seen with methylprednisolone use. Hospital and intensive therapy unit stay were significantly shortened
with trimetazidine and vitamin E use, respectively. Markers of liver parenchymal injury were significantly
lower in the methylprednisolone, trimetazidine, dextrose and ulinastatin groups compared with their
respective controls (placebo or no intervention).
Discussion: Methylprednisolone, trimetazidine, dextrose and ulinastatin may have protective roles
against IR injury in liver resection. However, based on the current evidence, they cannot be recommended
for routine use and their application should be restricted to RCTs.
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Introduction
Elective liver resection is performed mainly for benign and malig-
nant liver tumours.1 The malignant tumours may arise primarily
within the liver (hepatocellular carcinoma and cholangiocarci-
noma) or represent metastases from malignancies of other
organs.1,2 More than 1000 elective liver resections are performed
annually in the UK alone.3
Blood loss during liver resection is one of the important factors
affecting perioperative outcomes.4–6 One of the methods used to
reduce blood loss during liver resection involves occluding the
blood flow to the liver. Various methods of vascular occlusion may
be used.7 Although the incidence of liver failure is not increased by
vascular occlusion, the enzymes indicative of liver parenchymal
injury are elevated after vascular occlusion.8
Ischaemia-reperfusion (IR) injury of the liver is a complex
multi-path process leading to the activation of inflammatory
pathways.9 Cellular injury results from events occurring during
This paper is a shortened and combined version of two Cochrane reviews
submitted to the Cochrane Hepato-Biliary Group.
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both the ischaemic and reperfusion phases.9 Various methods
have been attempted to decrease the reperfusion injury associated
with prolonged duration of vascular occlusion, including the use
of ischaemic preconditioning,10,11 in situ cooling12,13 and pharma-
cological agents.
Many pharmacological agents have been shown in experimen-
tal models to ameliorate liver IR injury.14,15 Examples include anti-
inflammatory agents such as methylprednisolone,16 antioxidants
such as a-tocopherol (vitamin E),17 and various vasoactive agents
such as dopamine and dopexamine.18,19 There are no systematic
reviews or meta-analyses of randomized controlled trials (RCTs)
to assess the benefits and harms of these agents.
Materials and methods
Identification of studies and data extraction
Randomized controlled trials (irrespective of blinding, language
or publication status) comparing one or more pharmacological
interventions vs. another pharmacological intervention or no
pharmacological intervention (irrespective of the time, dose or
pharmacological class of the administered drug) were included.
Quasi-randomized studies (in which the methods of allocating
participants to a treatment are not strictly random, but instead
use, for example, date of birth, hospital record number or alter-
nation as a method of allocation) were excluded from the review
regarding benefits, but included for side-effects resulting directly
from the pharmacological intervention. The Cochrane Hepato-
Biliary Group Controlled Trials Register (Issue 4, 2008), the
Cochrane Central Register of Controlled Trials (CENTRAL) in the
Cochrane Library (Issue 4, 2008), MEDLINE (1951–January
2009), EMBASE (1974–January 2009) and the Science Citation
Index Expanded (1945–January 2009) were searched.20 The refer-
ences of the identified trials were searched to identify further
relevant trials. The following medical subject heading (MeSH)
terms were used in the search: ‘ischaemia’; ‘reperfusion’; ‘injury’;
‘liver’; ‘hepatectomy’; ‘reperfusion injury’; ‘gabexate’; ‘steroids’;
‘glucocorticoid’; ‘allopurinol’; ‘prostaglandin’; ‘amrinone’; ‘dopex-
amine’; ‘dopamine’; ‘antioxidant’; ‘bucillamine’, and ‘acetylcys-
teine’. Equivalent free-text search terms were used in the search
strategy. A filter for identifying the RCTs recommended by the
Cochrane Collaboration21 was used to filter out non-randomized
trials in MEDLINE and EMBASE.
Two reviewers (MA-A and KG) identified the trials for inclusion
and extracted population characteristics, details of the liver resec-
tion and vascular occlusion, and data on the liver background,
outcome measures and risk of bias in the trials.
Outcome measures
The primary outcomes of interest were: mortality and liver
failure/decompensation (however, defined by the authors). Sec-
ondary outcomes of interest were: perioperative morbidity (post-
operative bleeding, bile leak, intra-abdominal infections, wound
infections, ascites); intensive therapy unit (ITU) stay; hospital
stay; blood transfusion requirements; blood loss; markers of liver
function (bilirubin, prothrombin time), and biochemical markers
of liver parenchymal injury (aspartate aminotransferase [AST],
alanine aminotransferase [ALT]).
Assessment of risk of bias
High risk of bias in RCTs results in an overestimation of interven-
tion effects.22 The risk of bias was assessed by the Cochrane
methodology.21,23,24 Briefly, RCTs with adequate generation of the
allocation sequence, adequate allocation concealment, adequate
blinding, freedom from incomplete outcomes, and freedom from
selective outcome reporting were considered to be at low risk of
bias.
Statistical analysis
The meta-analyses were performed according to the recommen-
dations of the Cochrane Collaboration21 and the Cochrane
Hepato-Biliary Group Module23 using the software package
RevMan 5.25 Whenever there were two or more trials in each
comparison, the risk ratio (RR) with 95% confidence interval (CI)
was calculated for dichotomous outcomes. For continuous out-
comes, mean difference (MD) or standardized mean difference
(SMD) (for outcomes such as prothrombin time, for which dif-
ferent authors used either the international normalized ratio
[INR] or prothrombin time as a percentage of normal) with 95%
CI were calculated. When there was only one trial in each com-
parison, the RR or MD with 95% CIs were calculated from the
data available from the reports using RevMan 5. The random-
effects model26 and the fixed-effects model were used in the pres-
ence of two or more trials for each comparison.27 In cases of
discrepancy between the two models, both results were reported;
otherwise only the results from the fixed-effects model were
reported. Heterogeneity was explored by chi-squared test with
significance set at a P-value of 0.10, and the quantity of heteroge-
neity was measured by I2.28 Standard deviation was calculated
from the standard error or from P-values according to the guide-
lines of the Cochrane Collaboration.21 The analysis was performed
on an intention-to-treat basis29 whenever possible. Otherwise, we
adopted the ‘available case’ analysis.
Results
Description of studies
The reference flow is shown in Fig. 1. A total of 636 references
were identified through the electronic searches of the Cochrane
Hepato-Biliary Group Controlled Trials Register and CENTRAL
in the Cochrane Library (n = 75), MEDLINE (n = 283),
EMBASE (n = 171) and the Science Citation Index Expanded (n
= 107). We excluded 161 duplicates and 427 clearly irrelevant
references through reading abstracts. Forty-eight references were
retrieved for further assessment. No references were identified
through scanning reference lists of the identified RCTs. Of the
48 references, 24 were excluded as they represented non-
randomized studies,30–43 a quasi-randomized study which did not
report adverse outcomes related to the pharmacological inter-
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vention,44 a protocol of a study45 or studies that did not use vas-
cular flow occlusion during liver resection.46–53 A total of 24
references describing 18 RCTs fulfilled the inclusion criteria.54–77
All the trials assessed the different pharmacological agents in
open liver resections. The important characteristics of the
included trials are summarized in Table 1. In the trials that
reported follow-up, patients were followed either until discharge
or until 30 days after surgery. The assessment of risk of bias in
the included trials showed that none of the trials were at low risk
of bias. The individual domains of bias risk assessment in each
trial are shown in Fig. 2.
Primary outcomes
Mortality
There was no difference in perioperative mortality between the
groups in any of the comparisons in which mortality was
reported (mannitol vs. placebo,62 RR 0.33, 95% CI 0.01–7.58;
sevoflurane vs. propofol,56 RR 1.13, 95% CI 0.07–17.34; vitamin
E vs. placebo,55 RR 0.74, 95% CI 0.07–7.56). None of the
deaths reported were caused by the study medication or liver
failure.
Liver failure
None of the trials that reported on liver failure showed statistically
significant differences between the groups (trimetazidine vs. pla-
cebo,70 RR 0.2, 95% CI 0.01–4.03; multivitamin antioxidant infu-
sion vs. control,57 RR 4.0, 95% CI 0.48–33.33; methylprednisolone
vs. control,54,59,67–69,77 RR 0.5, 95% CI 0.10–2.63; ulinastatin vs.
gantaile,63 RR 0.31, 95% CI 0.04–2.68). None of the participants in
the comparisons (prostaglandin E1 vs. placebo,73 pentoxifylline vs.
control,72 prostaglandin E1 vs. control,72 sevoflurane vs. propo-
fol56) developed liver failure.
Secondary outcomes
Perioperative mortality
There was no statistically significant difference in perioperative
morbidity in any of the comparisons. Reported perioperative
morbidities are summarized in Table 2.
ITU and hospital stay
The postoperative ITU stay was reported to be significantly
shorter in the vitamin E compared with placebo groups, although
the exact length of stay was not provided for each group.55 None of
the remaining comparisons reported any significant difference in
postoperative ITU stay.
Postoperative hospital stay was significantly shorter in the tri-
metazidine compared with placebo groups70 (MD -3.0 days, 95%
CI -3.57 to -2.43) and the methylprednisolone compared with
control groups54,59,65,67–69,77 using the fixed-effects model (MD
-1.69 days, 95% CI -2.90 to -0.47), but not the random-effects
model (MD -1.07 days, 95% CI -3.36 to -1.21). None of the
remaining comparisons reported any significant difference in
length of postoperative hospital stay.
Blood transfusion requirements and blood loss
Blood transfusion requirements were significantly lower in the
methylprednisolone compared with control groups54,59,65,67–69
(SMD -0.68, 95% CI -1.06 to -0.31). None of the remaining
comparisons reported any significant difference in blood transfu-
sion requirements.
None of the comparisons showed any significant difference in
the rate of blood loss.
Markers of function
The bilirubin level was significantly lower in the methylpredniso-
lone compared with control groups on the first postoperative day
Figure 1 Flow chart of identified, in-
cluded and excluded references. RCT,
randomized controlled trial
References retrieved for more 
detailed evaluation 
(n = 48) 
References excluded (n = 588) 
   Duplicates (n = 161) 
   Identified as irrelevant by  
       reading abstracts (n = 427)  
Appropriate RCTs to be 
included in systematic review 
(n = 18, 24 references) 
References excluded (n = 24) 
   Non-randomized trials (n = 14) 
   Quasi-randomized trials (n = 1) 
   Protocol only (n = 1) 
   No vascular occlusion (n = 8) 
References identified through 
searches of databases 
(n = 636) 
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(POD)54,59,67–69,77 (MD -15.66, 95% CI -20.77 to -10.55), second
POD54,59,67–69 (MD -18.64, 95% CI -27.78 to -9.50) and
fifth POD54,59,67–69 (MD -8.72, 95% CI -15.65 to -1.79). The
bilirubin level was reported to be significantly lower in the ulin-
astatin compared with gantaile groups on the third POD, although
exact levels were not provided for each group.63 None of the
remaining comparisons reported any significant differences in
postoperative bilirubin level.
Prothrombin time was significantly improved in the methyl-
prednisolone compared with control groups on the first
POD54,59,67–69,77 (SMD -0.58, 95% CI -0.97 to -0.19) and second
POD54,59,67–69 (SMD -1.07, 95% CI -1.56 to -0.58). None of the
remaining comparisons reported any significant differences in
postoperative prothrombin times.
Enzyme markers of liver injury
Postoperative AST and ALT levels that were reported to show
significant differences between groups are summarized in Table 3.
None of the remaining comparisons reported any significant dif-
ferences in postoperative AST or ALT levels.
Side-effects
Two of the pharmacological interventions resulted in side-effects.
Pentoxifylline caused nausea and vomiting in 46% of participants,
who consequently failed to receive all the doses of study medica-
tion. One patient in the vitamin E group complained of a
headache.
Discussion
Effectiveness
None of the interventions resulted in a decrease in mortality, liver
failure or perioperative morbidity. However, some of the interven-
tions resulted in improvement in secondary outcomes such as
length of hospital stay, markers of liver function and enzyme
markers of liver injury. These interventions were methylpredniso-
lone, trimetazidine, dextrose and ulinastatin. These are discussed
in further detail.
Methylprednisolone
Methylprednisolone is a glucocorticoid steroid which acts as an
anti-inflammatory agent, reducing inflammatory markers and
apoptotic cell count in experimental liver IR injury.16 Three trials
evaluated methylprednisolone.54,59,65,67–69,77 Methylprednisolone
decreased hospital stay and blood transfusion requirements. It
also improved liver function and showed a trend favouring a
decreased postoperative complication rate. However, there was
considerable heterogeneity among the trials. The trial by Ald-
righetti et al.54,59,67–69 generally showed beneficial effects of the
steroid, but the other two trials (Muratore et al.,65 Yamashita
et al.77) did not demonstrate any such benefits.
These differences may reflect the much higher dose of the
steroid administered in the trial by Muratore et al.65 In all three
trials, methylprednisolone was administered as a single intrave-
nous dose preoperatively because the biological actions of this
steroid last for 36 hours78 and therefore cover both the early and
delayed phases of IR injury. Two of the trials used a dose of 500 mg
(Yamashita et al.,77 Aldrighetti et al.54,59,67–69), which results in
blood and liver tissue levels that significantly attenuate postopera-
tive inflammatory pathways,79 whereas the third trial (Muratore
et al.65) used a dose of 30 mg/kg based on previous work showing
a decrease of inflammatory markers in patients who were admin-
istered methylprednisolone at this dose.41 This translates to a dose
approximately four times that used in the other trials for an
average 70-kg man.
Figure 2 Individual methodological quality criteria for each trial
included
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Other possible explanations for the differences observed
between the trials may reflect the type of liver ischaemia, the
length of liver ischaemia, and the proportion of trial participants
undergoing major liver resection. In the trial by Aldrighetti
et al.,54,59,67–69 intermittent portal triad clamping (PTC) was used.
The other two trials65,77 used continuous PTC. In a recent
Cochrane review7 intermittent PTC tended to produce better out-
comes than continuous PTC. Aldrighetti et al.54,59,67–69 also per-
formed a multivariate analysis in which the methylprednisolone
group had significantly lower ALT and bilirubin levels compared
with the control group when the total liver ischaemia time was
>30 min or when the liver volume resected amounted to >60% of
liver volume. This multivariate analysis supports the results of
the three trials under this comparison. This is because the trial
(Aldrighetti et al.54,59,67–69) with the longest mean ischaemic time
(47.6 min) and highest proportion of participants undergoing
major liver resection (72%) reported the most significant
improvements in ALT and bilirubin in the postoperative period
compared with the other two trials (Yamashita et al.,77 Muratore
et al.65). The Muratore et al.65 trial had a mean ischaemic time of
39.2 min and 53% of all trial participants underwent a major
resection, whereas the Yamashita et al.77 trial did not report
ischaemic time and only 33% of its participants underwent a
major resection.
Recognized side-effects of steroid use, such as infection, poor
wound healing and glucose intolerance, were not reported in these
trials to any greater extent in the methylprednisolone groups. This
is most probably the result of the single-dose treatment method
adopted in these trials as the aforementioned side-effects are
usually related to longer periods of treatment with steroids. Meth-
ylprednisolone is an immunomodulator which affects various
immunological pathways, many of which are involved in the
pathophysiology of tumour development, progression and recur-
rence.80 Theoretically, it is possible that methylprednisolone use
could increase cancer progression and recurrence. Therefore,
future trials evaluating methylprednisolone in cancer patients
Table 2 Perioperative morbidity
Comparison Postoperative
bleeding
RR (95% CI)
Bile leak
RR (95%
CI)
Intra-abdominal
infections
RR (95% CI)
Wound
infections
RR (95% CI)
Ascites
RR (95%
CI)
Multivitamins vs. control57 0.14 (0.01–2.63) Not reported Not reported Not reported Not reported
Methylprednisolonea vs. control54,59,67–69,77 0.34b (0.01–8.14) 0.34 (0.01–8.14) 0.94c (0.06–13.82) 0.25 (0.03–2.15) 2.83c (0.12–64.89)
Sevoflurane vs. propofol56 0.23 (0.01–4.52) 1.13 (0.07–17.34) 0.16 (0.01–3.00) Not reported Not reported
Prostaglandin E1 vs. placebo73 Not reported 0.5 (0.05–4.81) Not reported 3.00 (0.13–67.06) Not reported
Trimetazidine vs. placebo70 Not reported 0.5 (0.05–5.28) 0.14 (0.01–2.67) 7.00 (0.37–131.06) Not reported
Ulinastatin vs. gantaile63 Not reported Not reported 0.94 (0.06–13.68) 0.63 (0.12–3.24) Not reported
aIn the trials evaluating methylprednisolone, Muratori et al. 200365 did not report on any perioperative morbidity
bOnly reported by Aldrighetti et al. 200654 (Finnazi et al. 2005,59 Pulitano et al. 2005, 200767–69)
cOnly reported by Yamashita et al. 200177
CI, confidence interval; RR, risk ratio
Table 3 Postoperative enzyme markers of liver injurya
Comparison Postoperative day AST, MD (95% CI) ALT MD (95% CI)
Dextrose vs. control74,75 1 -107.20 (-1.53 to -0.83) -123.3 (-182.47 to -64.13)
5 -89.7 (-133.04 to -6.36) -191.0 (-243.15 to -138.85)
Methylprednisolone vs. control54,59,67–69 2 -117.0 (-221.03 to -12.97) -125.0 (-239.48 to -10.52)
Trimetazidine vs. placebo70 1 -29.0 (-56.92 to -1.08) -30.0 (-59.50 to -0.50)
3 -20.0 (-39.69 to -0.31) -19.0 (-37.71 to -0.29)
5 -7.0 (-13.56 to -0.44) -15.0 (-29.75 to -0.25)
7 -8.0 (-15.37 to -0.63)
10 -5.0 (-9.90 to -0.10)
Sevoflurane vs. propofol56 Peak levels -254.18 (-450.59 to -57.77)
Ulinastatin vs. gantaileb63 AST on 3
ALT on 1, 3, 7
Exact value not reported Exact values not reported
Vitamin E vs. placeboc55 1 to 6 Area under curve. Exact value not reported
aOnly significant results are shown
bThe trial authors reported a significant difference between the groups but did not provide the exact numerical values
cThe trial authors reported a significant reduction in AST levels on days 1–6 postoperatively as measured by the area under the curve
AST, aspartate aminotransferase; ALT, alanine aminotransferase; CI, confidence interval; MD, mean difference
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should ensure longterm follow-up to monitor disease recurrence
and survival.
Given the possibility that the protective effects of methylpred-
nisolone become more apparent as the extent of liver resection
increases (methylprednisolone has a greater protective effect when
>60% of liver volume is resected), as well as in the presence of
chronic liver disease (the protective effect increases in patients
with chronic liver disease or cirrhosis), according to the method of
vascular occlusion (the protective effect increases in intermittent
vascular occlusion), and depending on the duration of ischaemia
(the protective effect increases when total ischaemic time is
>30 min), further research is warranted to clarify the benefits, or
otherwise, of methylprednisolone in these subgroups.
Trimetazidine
Trimetazidine is an antianginal drug that works by shifting cellu-
lar energy metabolism from fatty acid oxidation to glucose
oxidation, leading to increased adenosine triphosphate (ATP)
production and reduced oxygen consumption.81 Trimetazidine
has been shown to decrease liver IR injury in experimental mod-
els.82 In the one trial that evaluated trimetazidine (Settaf et al.70),
there were no mortalities and no significant differences in rates of
liver decompensation or perioperative morbidity. However, post-
operative AST and ALT levels were significantly lower in the
trimetazidine group compared with the placebo group. Further-
more, hospital stay was significantly shorter in the trimetazidine
group. Trimetazidine was administered at 40 mg twice per day
starting 5 days before the procedure until the day of surgery. The
authors of this trial admit that their dosing regimen may not have
been optimal and further trials evaluating the optimal dose–
response relationship will be needed. There were no side-effects
reported. Based on the results of this trial, trimetazidine may have
a role in protecting the liver during resection under vascular
occlusion. However, further investigations including trials to
evaluate the optimal time and dose of administration, as well as
liver function, are required.
Dextrose
Dextrose elevates liver glycogen stores and ATP content, thereby
maintaining hepatocyte and mitochondrial membrane integrity
and leading to a reduction in hepatocyte necrosis.74,75 One trial
evaluated dextrose (Tang et al.74,75). Dextrose decreased the AST
and ALT levels. A dose of 250 ml of 25% dextrose with 10 units of
insulin and 10 ml of 10% potassium chloride was administered
four times daily on the preoperative day. The timing and dose of
dextrose were chosen to significantly elevate the hepatic glycogen
content immediately prior to ischaemia. There were no reported
side-effects of the study medication. Based on these results, dex-
trose may play a role in liver protection during resection under
vascular control. However, this trial failed to report on many
outcomes of relevance, including mortality and liver decompen-
sation. Therefore, further trials of high methodological quality to
assess these and the other outcomes of interest are needed.
Ulinastatin
Ulinastatin is a protease inhibitor that acts by reducing the acti-
vation of white blood cells and the release of inflammatory cyto-
kines in liver IR injury.83 One trial (Li & Liang63) evaluated
ulinastatin and gantaile. There was no reported mortality in this
clinical trial. Ulinastatin lowered the AST, ALT and bilirubin levels
without affecting rates of liver decompensation, perioperative
morbidity or length of hospital stay. Ulinastatin was commenced
at a dose of 10 000 IU intraoperatively, followed by twice daily
administration at the same dose combined with vitamin K1 and
glucose for 5 consecutive days. The dosage at which gantaile was
administered was not reported by the investigators, but vitamin
K1 and glucose were administered as for ulinastatin. The authors
did not explain why they had chosen this dosing regime. There
were no reported side-effects of the study medication. Based on
these results, it seems that ulinastatin may offer a protective role in
elective liver resections under vascular occlusion. Further trials of
good methodological quality are required.
Other interventions
None of the remaining interventions showed any consistent
benefit in any of the outcome measures. Furthermore, two of these
interventions, utilizing prostaglandin E1 and multivitamin
antioxidants, were reported on by more than one RCT each. The
results of the outcome measures in each of these interventions
were consistent in the different trials.
Relative effectiveness of the pharmacological agents
The number of trials under each comparison was so few that an
indirect comparison is unlikely to yield any meaningful infer-
ences. Therefore, we did not attempt to infer the relative effective-
ness of the pharmacological agents from the available data.
Subgroup analysis
Patients with liver cirrhosis, steatosis or undergoing major liver
resections are known to be at high risk for developing IR injury.
For this reason, we intended to perform a subgroup analysis on
each of these. However, the lack of numerical reporting of
outcome measures in each of these subgroups and the few trials
included within each comparison made us unable to do so.
Safety
The pharmacological agents used in the RCTs cited in this review
can be divided into those that are clinically licensed, for which the
side-effects have been well profiled, and those that are not clini-
cally licensed. The clinically licensed drugs include trimetazidine,
vitamin E, multivitamin infusion, pentoxifylline, mannitol,
amrinone, methylprednisolone, allopurinol, dextrose, dopexam-
ine, dopamine, sevoflurane and propofol. The side-effects
reported for these interventions were nausea and vomiting in 46%
of patients in the pentoxifylline group, who failed to receive all the
doses of study medication as a consequence. In addition, one case
of headache was reported in the vitamin E group and four cases of
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liver decompensation were reported in the multivitamin infusion
group. Although this level of incidence does not attain statistical
significance compared with the control group, these liver decom-
pensations raise concerns about the safety of the multivitamin
antioxidant infusion in liver resections. This is because liver dec-
ompensation or failure is considered a direct indicator of liver
injury. Thus, using the multivitamin antioxidant mixture may
actually cause harm in the clinical setting of this review. There has
been no previous work showing a causal relationship between
multivitamin intake and liver failure. However, a comprehensive
meta-analysis of 47 RCTs at low risk of bias investigating antioxi-
dant consumption, including multivitamin combinations,
showed a significant increase in mortality.84 Therefore, it may be
possible that multivitamin usage in the setting of liver resections
with vascular occlusion is not without serious consequences.
Further basic animal research is needed to confirm or reject this
theory.
Quality of evidence and future trials
None of the included RCTs were at low risk of bias. This reflects
poor trial design. This is one of the few instances in the field of
hepatopancreatobiliary surgery in which trials with adequate ran-
domization and blinding can be conducted. Poor trial design can
lead to erroneous conclusions (systematic errors).22 Only two
trials (Marx et al.,64 Muratore et al.65) provided sample size calcu-
lations, but even these trials were not powered to measure any
differences in the clinically relevant outcomes. The number of
trials included under each comparison was few. Thus, there is a
high risk of type I (false positive) and type II (false negative) errors
(random errors). Therefore, the risk of both random and system-
atic errors in the trials assessed in this review is high. Aldrighetti
et al.54 observed that methylprednisolone was more beneficial in a
subgroup of patients. Stratification of patients based on the back-
ground liver (cirrhosis, steatosis, normal liver) and the extent of
liver resection (major or minor liver resection) will allow the
identification of specific subgroups for which the pharmacologi-
cal interventions are beneficial.
The length of follow-up in the trials should be appropriate.
Most of the trials included in this review followed patients only
until their discharge. Recently, there have been concerns about
using vascular occlusion in liver resections carried out for malig-
nancy as it is hypothesized that IR injury can increase the rate of
recurrence.85 Therefore, interventions that influence IR injury
may also influence disease recurrence and patient survival. The
length of follow-up in the trials should be long enough to assess
patient survival and disease recurrence rates.
Future trials evaluating pharmacological interventions in liver
resections under vascular occlusion should include patient-
oriented outcomes. Direct markers of liver function or dysfunc-
tion, such as postoperative morbidity, should be given more
priority than surrogate markers of liver function, such as enzyme
markers of liver injury. This is supported by the use of validated
systems for classifying postoperative surgical complications.86 The
measurement of clinically oriented outcomes and potential sur-
rogate markers will allow the simultaneous assessment of inter-
ventions and the validation of surrogate markers so that future
randomized clinical trials can be powered to measure any vali-
dated surrogate outcome.
Conclusions
Methylprednisolone, trimetazidine, dextrose and ulinastatin may
have protective roles against IR injury in liver resections per-
formed under vascular occlusion. However, based on the current
evidence, they cannot be recommended for routine use and their
application should be restricted to RCTs.
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